Scientist I, Drug Metabolism and Pharmacokinetics
Boehringer Ingelheim
Summary
Boehringer Ingelheim is seeking a highly motivated Scientist I to join the Drug Metabolism & Transport (DM&T) group at our US headquarters in Ridgefield, CT.
Job description
As a Scientist I, you will work closely with DM&T colleagues, conducting in vitro studies to evaluate the absorption, distribution, metabolism and excretion (ADME) of small molecule drug candidates. Studies will include the mechanistic interaction of drugs, metabolites, and selected reference compounds with drug metabolizing enzymes. Additionally, studies may include evaluating the distribution of investigational compounds into cells or tissues using advanced technology and radiolabeled materials.
Duties & Responsibilities
- Conduct and report data from in vitro metabolism studies using various cellular and subcellular systems, e.g. microsomes, hepatocytes, and transfected cells
- Operate liquid chromatography tandem mass spectroscopy (LC-MS/MS) instrumentation
- Contribute to establishing and implementing strategies to rapidly onboard new technologies that enable achievement of portfolio goals
- Utilize advanced, cutting-edge computing systems and automated equipment to accelerate and optimize progression of our investigational compounds through clinical development
- Comply with all applicable regulations, ensure that work performed in area of responsibility is conducted in a safe and compliant manner, and maintain proper records in accordance with SOPs and policies
Requirements
- Bachelor's Degree from an accredited academic institution in Pharmacology, Biology, Chemistry, Biochemistry, or other relevant field of study or equivalent experience in a related field required
- Experience conducting experiments to evaluate the interaction of molecules with drug metabolizing enzymes would be highly beneficial
- An understanding of the foundational principles of enzyme kinetics would be advantageous
- Experience with culturing cells, operating LC/MS systems, and the safe use of radioactivity would be beneficial
- Experience with AI-based tools and their application to laboratory-based tasks
- Ability to communicate effectively both orally and in writing in an interdisciplinary environment
Eligibility Requirements
- Must be legally authorized to work in the United States without restriction
- Must be willing to take a drug test and post-offer physical (if required)
- Must be 18 years of age or older
Requirements
- Bachelor's Degree in Pharmacology, Biology, Chemistry, Biochemistry, or other relevant field of study or equivalent experience in a related field
- Experience conducting experiments to evaluate the interaction of molecules with drug metabolizing enzymes
- Understanding of the foundational principles of enzyme kinetics
- Experience with culturing cells, operating LC/MS systems, and the safe use of radioactivity
- Experience with AI-based tools and their application to laboratory-based tasks
- Ability to communicate effectively both orally and in writing in an interdisciplinary environment
- Must be legally authorized to work in the United States without restriction
- Must be willing to take a drug test and post-offer physical (if required)
- Must be 18 years of age or older
Benefits
- Medical, Dental & Vision
- Retirement Savings
- Paid Time Off
- Paid Holidays
- Disability Insurance
- Life Insurance
- Relocation Assistance
- Discretionary Bonus
Company overview
Boehringer Ingelheim is a leading global research-driven biopharmaceutical company founded in 1885 and headquartered in Ingelheim am Rhein, Germany. As one of the world's top 20 pharmaceutical companies and the largest privately-owned pharmaceutical firm, it operates across three main business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. The company focuses on developing innovative therapies for diseases with high unmet medical needs, including cardiometabolic diseases, oncology, respiratory diseases, immunology, central nervous system disorders, and retinal health. With over 54,500 employees across 78 countries, Boehringer Ingelheim generated approximately €26.8 billion in revenue in 2024. The company maintains a strong research and development network with facilities in Germany, the United States, Austria, Japan, and Switzerland, investing significantly in advancing treatments for both human and animal health. Notable products include Jardiance (empagliflozin) for diabetes, Ofev (nintedanib) for pulmonary fibrosis, Spiriva (tiotropium) for respiratory conditions, and Pradaxa (dabigatran) for anticoagulation therapy.